Caldwell Sutter Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Caldwell Sutter Capital’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.76K	Hold	6	–	–	﹤0.01%	815
2026 Q1	$1.67K	Hold	6	–	–	﹤0.01%	771
2025 Q4	$1.82K	Hold	6	–	–	﹤0.01%	755
2025 Q3	$1.68K	Hold	6	–	–	﹤0.01%	756
2025 Q2	$1.45K	Hold	6	–	–	﹤0.01%	752
2025 Q1	$1.46K	Hold	6	–	–	﹤0.01%	766
2024 Q4	$1.97K	Hold	6	–	–	﹤0.01%	747
2024 Q3	$2.01K	Hold	6	–	–	﹤0.01%	758
2024 Q2	$1.64K	Hold	6	–	–	﹤0.01%	778
2024 Q1	$2.08K	Hold	6	–	–	﹤0.01%	754
2023 Q4	$1.94K	Hold	6	–	–	﹤0.01%	766
2023 Q3	$2.15K	Hold	6	–	–	﹤0.01%	722
2023 Q2	$2.27K	Buy	+6	New	+$2.44K	﹤0.01%	726

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Caldwell Sutter Capital's BIO Position: Q2 2026 in Review

Caldwell Sutter Capital held its Bio-Rad Laboratories Class A (BIO) position steady in Q2 2026 at 6 shares worth $1.76K. The position accounts for ﹤0.01% of the portfolio, ranked #815.

Caldwell Sutter Capital first reported a position in BIO in Q2 2023 and has held it in 13 quarters since. The position peaked at $2.27K in Q2 2023. 399 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

Caldwell Sutter Capital held 6 shares of Bio-Rad Laboratories Class A worth $1.76K as of Q2 2026.
Caldwell Sutter Capital left its Bio-Rad Laboratories Class A share count unchanged in Q2 2026.
Bio-Rad Laboratories Class A made up ﹤0.01% of Caldwell Sutter Capital's portfolio in Q2 2026, its #815 holding.
Caldwell Sutter Capital first reported a position in Bio-Rad Laboratories Class A in Q2 2023 and has held it in 13 quarters since.
Caldwell Sutter Capital's Bio-Rad Laboratories Class A position peaked at $2.27K in Q2 2023.
399 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Caldwell Sutter Capital's 13F filing for Q2 2026, filed 5 Aug 2026.